Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →
CLEATUS
Get CLEATUS

Toolkits for Dissemination of Genomic Technologies

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Institutes of Health, through the National Human Genome Research Institute, is initiating the Toolkits for Dissemination of Genomic Technologies program to bridge the gap between the invention of wet-lab technologies and their widespread adoption by the scientific community. This initiative supports developers in creating integrated toolkits that include custom reagents, hardware, annotated protocols, and computational pipelines. In some instances, the program may also provide hands-on methods training and workshops to ensure the technology is implemented effectively. The primary goal of this forecast is to allow developers to obtain independent validation and user feedback, which will be used to refine and mature genomic technologies for broader use. Managed by the Department of Health and Human Services under NAICS code 541714, the program focuses on lowering barriers to technology adoption and enhancing the accessibility of innovative genomic interrogation methods.

General Info

NHGRI funds integrated genomic toolkits with reagents, protocols, training to promote widespread adoption.

Agency

Department Of Health And Human Services → National Institutes Of Health

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
Contacts1 person available
OfficeUSA
Organization / AgencyDepartment Of Health And Human Services → National Institutes Of Health
Office AddressUSA
Contacts
Ian Nova
contact@example.gov
+1 (555) 000-0000

Full Description

Show more

The National Human Genome Research institute (NHGRI) funds wet-lab technology development across its portfolios, resulting in invention of innovative methods to interrogate and understand the genome. However, there is often a gap between the technology and methods development in individual inventor labs and the wide-spread deployment of these approaches to the broader scientific community. The Toolkits for Dissemination of Genomic Technologies initiative will create a pathway to lower this barrier to technology adoption by supporting the dissemination efforts of tool and technology developers in the form of an integrated toolkit containing the necessary components and information required to implement the technology. A kit would include custom reagents and/or hardware along with annotated and updated protocols, computational pipelines, and if appropriate, would be accompanied by hands-on methods training and workshops for the scientific community. Using this dissemination approach, developers would gain independent validation of their technologies and feedback from users. Feedback from toolkit users would then be applied by developers to inform further maturation of these genomic technologies, priming methods for more wide-spread adoption by the scientific community. 

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Preclinical & Translational Research SupportThis subcontract for Preclinical and Translational Research Support involves providing specialized laboratory services and preclinical testing to prime contractors working on Defense Health Agency lupus research projects. The scope of work focuses on supporting the transition from laboratory research to clinical application through the development of animal models, in-vitro and in-vivo modeling, and preclinical toxicity testing. The primary deliverables include validated models and comprehensive preclinical test results. The project is managed under the Department of Defense for the Defense Health Agency and is categorized under NAICS code 541714. Performance of the contract will take place in Frederick, Maryland. Interested parties should note the response deadline of November 16, 2026.
Defense Health Agency

POSTED

about 13 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Federal
Patient Quality of Life (QoL) Clinical StudiesThis subcontract focuses on conducting patient-centric clinical research for the Defense Health Agency to evaluate factors affecting the quality of life for lupus patients. The scope of work includes comprehensive clinical trial management, the design of patient surveys, psychosocial assessments, and detailed health outcomes research. The primary objective is to generate and deliver clinical study reports and outcome data to prime contractors. The project is categorized under NAICS code 541714 and will be performed in Frederick, Maryland. Interested parties should note that the response deadline is November 16, 2026, following a posting date of October 14, 2026.
Defense Health Agency

POSTED

about 13 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Federal
Disease Mechanism & Intervention ResearchThis subcontract opportunity involves conducting specialized research into lupus disease mechanisms and analyzing patient responses to medical interventions to support prime contractors on Defense Health Agency projects. The scope of work focuses on translational research, pharmacological studies, and the mapping of disease pathways to deliver critical analysis of intervention response data. The project is associated with NAICS code 541714 and will be performed in Frederick, Maryland. Interested parties should note that the solicitation was posted on October 14, 2026, with a response deadline set for November 16, 2026.
Defense Health Agency

POSTED

about 13 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Federal
Lupus Genetic & Biological Subset ResearchThe Lupus Genetic and Biological Subset Research subcontract involves providing specialized biological and genetic analysis to support prime contractors on Defense Health Agency research projects. The scope of work focuses on identifying and categorizing lupus patient subsets to enable targeted treatment through genomic sequencing, biomarker identification, biological assay development, and detailed patient cohort analysis. The primary deliverable for this effort is the provision of categorized biological and genetic data sets. This project is managed under the Department of Defense for the Defense Health Agency, with performance taking place in Frederick, Maryland. The opportunity was posted on October 14, 2026, with a response deadline of November 16, 2026. The work is classified under NAICS code 541714, reflecting its focus on research and development in the biotechnology field.
Defense Health Agency

POSTED

about 13 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Federal
RFI Lupus Research Program (LRP) Public
Solicitation # HT9427RFI2027LRP
The Defense Health Agency, through the Congressionally Directed Medical Research Programs, has issued a Request for Information under solicitation number HT9427RFI2027LRP to gather feedback for the Lupus Research Program. This initiative aims to inform future focus areas and research funding opportunities for fiscal year 2027. The program is specifically seeking input from academia, industry, non-profit organizations, federal agencies, and the general public to identify critical gaps in the field and underfunded research areas. Strategic goals include improving the quality of life for patients, gaining insight into disease mechanisms and heterogeneity, and advancing the understanding of lupus patient subsets to optimize treatment. This action is strictly for information and planning purposes and does not constitute a formal solicitation, request for proposals, or request for quotations. Consequently, no contract will be awarded based on this announcement, and there are no established deliverables or periods of performance. Interested parties are requested to provide their feedback via Survey Monkey by November 16, 2026, at 4:00 PM EST. While previous appropriations from fiscal years 2017 through 2026 totaled 75 million dollars, funds for fiscal year 2027 have not yet been appropriated.
Defense Health Agency

POSTED

about 13 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
Preclinical In Vivo Efficacy Testing
National Institutes Of Health

POSTED

2 days ago

DEADLINE

in 4 months
View Details
NAICS: 541714
New
Grant
Specialized Vaccine Formulation Services
National Institutes Of Health

POSTED

2 days ago

DEADLINE

in 4 months
View Details
NAICS: 541714
New
Grant
Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-024
The National Institutes of Health, under the Department of Health and Human Services, is soliciting applications for RFA-AI-28-024 to support the research and preclinical development of highly efficacious malaria vaccines. The initiative focuses on utilizing structure-based immunogen design, improved formulations, and combination vaccines to create long-lasting protection that can serve as a model for other mosquito-borne diseases. This funding opportunity is structured as a phased award, consisting of an R61 exploratory phase for up to three years with annual direct costs up to 400,000 dollars, and an R33 development phase for up to two years with annual direct costs up to 750,000 dollars. The maximum total project period is five years, and clinical trials are strictly prohibited. Applications will be evaluated through the NIH peer review system based on the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Key requirements include the establishment of quantifiable R61 transition milestones and clear translational Go/No-go criteria for vaccine candidates. Applicants must maintain active SAM registration and provide a Data Management and Sharing Plan. Additionally, recipients must adhere to strict cybersecurity protocols modeled after the NIST framework, including multifactor authentication and a 48-hour incident notification requirement, and ensure all research involving human subjects or vertebrate animals complies with federal regulations and ethical guidelines.
National Institutes Of Health

POSTED

2 days ago

DEADLINE

in 4 months
View Details
NAICS: 541714
New
Grant
High-Throughput Functional Genomic AssayingThis subcontract, titled High-Throughput Functional Genomic Assaying, supports National Institutes of Health and NHGRI research projects by providing experimental testing of genomic variants. The scope of work involves implementing high-throughput assays to perturb variants and executing functional interpretation strategies utilizing CRISPR-based systems and high-throughput screening platforms. The selected provider is responsible for delivering raw molecular and cellular data along with all associated metadata. The project is managed under the Department of Health and Human Services and requires strict adherence to 45 CFR Part 46 regulations regarding human subjects research. The opportunity was posted on October 9, 2026, with a response deadline of December 14, 2026. It is categorized under NAICS code 541714 for research and development in biotechnology.
National Institutes Of Health

POSTED

6 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Specialized Phenotypic Assay Development/ExecutionThis subcontract, titled Specialized Phenotypic Assay Development/Execution, supports prime contractors on NIH IGVF Consortium projects under the Department of Health and Human Services. The primary objective is the collection of robust phenotypic data through the execution of imaging, proteomics, and transcriptomics assays designed to measure the impacts of variant interactions. To achieve this, the contractor will utilize advanced technical equipment, including mass spectrometers, flow cytometers, and high-content imaging systems. The scope of work emphasizes the delivery of high-quality phenotypic data sets while adhering to strict quality control standards for high-throughput data. This opportunity falls under NAICS code 541714 and was posted on October 9, 2026, with a response deadline of December 14, 2026.
National Institutes Of Health

POSTED

6 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Senescence-Specific Reagent and Tool ManufacturingThis subcontract, titled Senescence-Specific Reagent and Tool Manufacturing, supports National Institutes of Health projects focused on senescence technologies. The selected provider will develop and supply innovative reagents, biospecimens, and tools for prime contractors, specifically focusing on the creation of markers for phenotypic identifiers and the manufacture of reagents to identify senescence heterogeneity within secretomes and tissue environments. The scope of work requires the use of biotechnology laboratory facilities for antibody production and protein synthesis, with a final delivery of validated assays and physical reagents. All operations must strictly adhere to NIH guidelines regarding human systems. The opportunity was posted on October 9, 2026, with a response deadline of November 23, 2026, falling under NAICS code 541714.
National Institutes Of Health

POSTED

6 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
Solicitation # RFA-RM-27-007
The National Institutes of Health, under the Department of Health and Human Services, is soliciting the development or adaptation of innovative senescence technologies (SenTecs) through solicitation RFA-RM-27-007. These technologies aim to identify, characterize, and understand senescent cell heterogeneity within tissue environments and secretomes to improve strategies for modulating these cells in human aging and disease. The program utilizes a five-year, milestone-driven award structure divided into two phases: a two-year UG3 phase focused on development and feasibility, and a three-year UH3 phase dedicated to optimization, refinement, and validation. Transition to the UH3 phase is not automatic and requires an administrative review at the end of year two. The final year of the award requires a collaborative demonstration project within the SenNet consortium. The NIH intends to commit 5.4 million dollars in total costs for fiscal year 2027 to fund up to nine awards, with direct cost caps of 400,000 dollars per year for the UG3 phase and 550,000 dollars per year for the UH3 phase. Applications are evaluated based on the importance of the research, scientific rigor, feasibility, and the expertise of the investigators. Required submissions include an Intellectual Property Strategy and a Data Management and Sharing Plan. Awardees must adhere to strict cybersecurity incident reporting, maintain a seven-year confidentiality agreement for non-public information, and ensure all technical assets and data are deposited into the SenNet Data Portal. Clinical trials are not allowed under this specific opportunity.
National Institutes Of Health

POSTED

6 days ago

DEADLINE

in about 1 month
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

New
Grant
Testing Centers for Evaluation of Somatic Cell Genome Editing Approaches for Translational Applications (U42 Clinical Trial Not Allowed)

POSTED

2 days ago

DEADLINE

N/A
View Details
New
Grant
Coordinating Center for the Claude D. Pepper Older Americans Independence Centers (OAICs)

POSTED

2 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Program (U19 Clinical Trial Optional)The National Institute on Alcohol Abuse and Alcoholism, under the Department of Health and Human Services, intends to issue a Notice of Funding Opportunity to continue the Collaborative Initiative on Fetal Alcohol Spectrum Disorders. This multidisciplinary research consortium focuses on a wide range of studies, including basic, clinical, translational, diagnostic, intervention, and prevention research aimed at addressing the lifelong physical, cognitive, and behavioral impairments caused by prenatal alcohol exposure. The program seeks to support high-priority needs such as improving early identification and diagnosis, validating interventions, and exploring the mechanisms of alcohol teratogenesis to reduce the incidence of these disorders. Successful projects must demonstrate strong integration with the broader consortium through the use of shared resources, coordinated data activities, and multidisciplinary expertise. This forecast indicates a research program where clinical trials are optional.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

9 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Centers for Research on Neglected Infectious DiseasesThe National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is establishing the Centers for Research on Neglected Infectious Diseases to combat communicable viral, bacterial, parasitic, and fungal infections. This initiative focuses on the epidemiology, pathogenesis, diagnosis, treatment, and prevention of parasitic neglected infectious diseases within endemic regions. By building sustainable in-country research capacity and expertise, the program aims to identify, contain, and mitigate these diseases at their source to protect global health and reduce the risk of spread within the United States. This opportunity is issued as a forecast by the Department of Health and Human Services and is governed by the Public Health Service Act and Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. Interested parties can coordinate with the Division of Microbiology and Infectious Diseases for further information. The program emphasizes a multidisciplinary approach to research and training to address the substantial morbidity and mortality associated with understudied infectious diseases.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

9 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
HIV Prevention and Alcohol (R61/R33 Clinical Trials Optional)The National Institutes of Health, under the Department of Health and Human Services, is offering a Phased Innovation Award to advance innovative HIV prevention interventions. This funding opportunity utilizes a two-stage R61/R33 structure to move research from initial development and feasibility testing to larger-scale efficacy and implementation studies. The initial R61 phase focuses on the development, refinement, and pilot testing of novel strategies to address critical scientific and operational questions, ensuring readiness for expanded evaluation across diverse populations. Upon the successful completion of R61 milestones, the R33 phase provides support for expanded testing of interventions and implementation strategies. These studies may evaluate the scalability, sustainability, and clinical management of HIV prevention interventions, specifically including integrated approaches that address alcohol use and related comorbidities. Interested parties can contact the HIV/AIDS and Alcohol Research Program for further information.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

14 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required)The National Institutes of Health is forecasting a Notice of Funding Opportunity to solicit applications for early to definitive clinical trials. This initiative seeks proposals testing a wide range of interventions, including drugs, devices, biologics, procedures, and behavioral or social interventions, provided they align with the research missions of the participating NIH Institutes, Centers, and Offices. The funding will utilize a bi-phasic, milestone-driven R61/R33 activity code with a maximum project period of seven years. The R61 phase focuses on planning activities, while the R33 phase supports the actual clinical trial. Although applications are not currently being accepted, this notice serves as an advance alert for investigators with expertise in trial design, implementation, and stakeholder engagement to begin developing collaborations and projects.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

16 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Continuation of the Exceptional Longevity Data Management and Coordinating Center (EL DMCC) (U24 Clinical Trial Not Allowed)The National Institute on Aging intends to issue a single U24 cooperative agreement award to support the continued operation and expansion of the Exceptional Longevity Data Management and Coordinating Center. Serving as the central hub for human longevity translational research, the center integrates deeply phenotyped cohorts and multi-omics datasets to enable cross-cohort analyses and collaborative research. Key responsibilities include data harmonization, the implementation of common data standards, and the management of the ELITE Portal, which provides the research community with secure access to analytical tools and cloud-based computational workspaces. The upcoming funding opportunity will require the Coordinating Center to expand its capabilities in artificial intelligence, machine learning, and the integration of diverse datasets across different species. Future objectives include the development of curated target knowledgebases for therapeutic targets, the enhancement of portal interoperability according to FAIR data principles, and the strengthening of community engagement through specialized training and workshops. This notice serves as a forecast to allow potential applicants to establish collaborations before the official solicitation is released.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

21 days ago

DEADLINE

N/A
View Details
NAICS: 541714
Grant
Immune Drivers of Autoimmune DiseaseThe National Institute of Allergy and Infectious Diseases seeks to support the Immune Drivers of Autoimmune Disease network to investigate the triggers and early mechanisms of autoimmunity in humans. The primary goal is to develop tools for risk prediction and staging, identify pre-clinical immune mechanisms, and utilize artificial intelligence and big data to prevent autoimmune diseases. This initiative emphasizes the creation of preclinical cohorts and the use of remote recruitment and sampling to advance medical research. The network will be managed by a Coordinating Center responsible for data harmonization, sample sharing, and the administration of an Infrastructure Opportunity Fund for collaborative research projects. This forecast, issued by the National Institutes of Health under the Department of Health and Human Services, establishes a framework for shared infrastructure and steering committee oversight to identify common pathways and prevention opportunities.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

21 days ago

DEADLINE

N/A
View Details
NAICS: 513130
Grant
NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)The National Institutes of Health, through the Department of Health and Human Services, is soliciting applications for the NLM Grants for Scholarly Works in Biomedicine and Health program. This initiative provides funding for the creation of book-length manuscripts and other integrative scholarly works, such as critical reviews and analytical syntheses, designed to benefit U.S. health professionals, scientists, and public health practitioners. The primary goal is to organize and disseminate biomedical and health-related knowledge to improve research, education, and clinical practice. This opportunity is listed as a forecast with a posted date of September 24, 2026. It specifically prohibits the use of clinical trials. Interested parties can contact the NLM Extramural Programs office for further information regarding the application process and program requirements.
Book Publishers

POSTED

21 days ago

DEADLINE

N/A
View Details
NAICS: 541714
Grant
Partnerships for Advancing Development of Diagnostics for Infectious DiseasesThe National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is seeking to establish partnerships between academic or small business investigators and industrial partners to advance the translational development of diagnostic tests for infectious diseases. This initiative focuses on moving diagnostics that have already demonstrated proof-of-concept through the commercialization process by aligning researchers with experienced industry partners to de-risk development and ensure products are fit for purpose. The program will be supported by a science advisory board and NIAID oversight, incorporating annual meetings and workshops to facilitate collaboration and knowledge exchange. This effort is authorized under the Public Health Service Act and federal regulations to ensure that promising diagnostic technologies are successfully translated into tools for treating and preventing infectious diseases.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

21 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE)The National Institute of Allergy and Infectious Diseases, under the Department of Health and Human Services, is forecasting the LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE) program. This initiative aims to bridge the gap between traditional clinical trial findings and real-world application by supporting collaborations on effectiveness trials, pragmatic trials, and hybrid effectiveness-implementation studies. The program focuses on the prevention and treatment of HIV, including associated coinfections and comorbidities, across all age groups and various points of care. The goal of the program is to advance cross-cutting research in epidemiology, implementation science, and clinical, behavioral, and social sciences. This effort aligns with the broader NIH mission to implement research advances in HIV/AIDS. The opportunity is authorized under the Public Health Service Act and relevant federal regulations, with administrative oversight provided by the Division of AIDS Epidemiology Branch.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

21 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Collaborative Centers in Children’s Environmental Health Research and Translation (P2C Clinical Trial Optional)The National Institutes of Health, under the Department of Health and Human Services, is seeking applications to establish a national network of Children's Environmental Health Research Translation Centers. These centers are designed to protect and improve children's health by developing scientific questions and public health interventions focused on translational research. A primary objective is to move evidence-informed biomedical findings into practical application for the wider community while mentoring a new generation of investigators in the field. Beyond research and translation, the program will function as a national resource to coordinate responses to emerging environmental exposures that impact children. The initiative emphasizes the creation of actionable strategies to prevent harm and ensure a healthy future for children through collaborative efforts within the environmental health community.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

21 days ago

DEADLINE

N/A
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS